Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The...
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
